Journal of Clinical Oncology, Vol 25, No 5 (February 10), 2007: pp. 479-485
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.07.5358
Circulating 25-Hydroxyvitamin D Levels Predict Survival in Early-Stage NonSmall-Cell Lung Cancer Patients
Wei Zhou,
Rebecca S. Heist,
Geoffrey Liu,
Kofi Asomaning,
Donna S. Neuberg,
Bruce W. Hollis,
John C. Wain,
Thomas J. Lynch,
Edward Giovannucci,
Li Su,
David C. Christiani
From the Departments of Environmental Health, Biostatistics, Nutrition, and Epidemiology, Harvard School of Public Health; Department of Medicine; Thoracic Surgery Unit, Department of Surgery, Massachusetts General Hospital; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute; Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Pediatric Nutritional Sciences, Darby Children's Research Institute, Medical University of South Carolina, Charleston, SC
Address reprint requests to Wei Zhou, MD, PhD, Occupational Health Program, Harvard School of Public Health, 665 Huntington Ave, Boston, MA 02115; e-mail: wzhou{at}hsph.harvard.edu
Purpose Our previous analyses suggested that surgery in the summertime with higher vitamin D intake is associated with improved survival in patients with early-stage nonsmall-cell lung cancer (NSCLC). We further investigated the results of circulating 25-hydroxyvitamin D (25[OH]D) levels on overall survival (OS) and recurrence-free survival (RFS) in NSCLC patients.
Patients and Methods Among 447 patients with early-stage NSCLC, data were analyzed using Cox proportional hazards models, adjusting for age, sex, stage, smoking, and treatment.
Results The median follow-up time was 72 months (range, 0.2 to 141), with 161 recurrences and 234 deaths. For OS, the adjusted hazard ratio (AHR) was 0.74 (95% CI, 0.50 to 1.10; Ptrend = .07) for the highest versus lowest quartile of 25(OH)D levels. Stratified by stage, a strong association was observed among stage IB-IIB patients (AHR, 0.45; 95% CI, 0.24 to 0.82; Ptrend = .002), but not among stage IA patients (AHR, 1.10; 95% CI, 0.62 to 1.96; Ptrend = .53). Similar effects of 25(OH)D levels were observed among the 309 patients with dietary information (AHR, 0.74; 95% CI, 0.46 to 1.17; Ptrend = .19). For the joint effects of 25(OH)D level and vitamin D intake, the combined high 25(OH)D levels and high vitamin D intake (by median) were associated with better survival than the combined low 25(OH)D levels and low vitamin D intake (AHR, 0.64; 95% CI, 0.42 to 0.98; Ptrend = .06). Again, stronger associations were observed among stage IB-IIB than IA patients. Similar effects of 25(OH)D levels and vitamin D intake were observed for RFS.
Conclusion Vitamin D may be associated with improved survival of patients with early-stage NSCLC, particularly among stage IB-IIB patients.
Supported by National Institutes of Health Grants No. CA 092824, CA074386, CA090578, ES/CA 06409, and ES00002 (D.C.C.); the American Institute for Cancer Research, the Flight Attendants Medical Research Institute Young Clinical Scientist Award, and NIH Grant No. CA119650-01A1 (W.Z.); the American Cancer Society Postdoctoral Fellowship (R.S.H.); and the Doris Duke Charitable Foundation and Sue's Fund (G.L.).
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
Related Correspondence
- Lung Cancer Survival: Vitamin D Could Be Just a Marker of Physical Fitness
Dirk Van Renterghem
JCO 2007 25: 5537-5538
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
K. D. Crew, M. D. Gammon, S. E. Steck, D. L. Hershman, S. Cremers, E. Dworakowski, E. Shane, M. B. Terry, M. Desai, S. L. Teitelbaum, et al.
Association between Plasma 25-Hydroxyvitamin D and Breast Cancer Risk
Cancer Prevention Research,
June 1, 2009;
2(6):
598 - 604.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. D. Crew, E. Shane, S. Cremers, D. J. McMahon, D. Irani, and D. L. Hershman
High Prevalence of Vitamin D Deficiency Despite Supplementation in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy
J. Clin. Oncol.,
May 1, 2009;
27(13):
2151 - 2156.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Janssens, A. Lehouck, C. Carremans, R. Bouillon, C. Mathieu, and M. Decramer
Vitamin D Beyond Bones in Chronic Obstructive Pulmonary Disease: Time to Act
Am. J. Respir. Crit. Care Med.,
April 15, 2009;
179(8):
630 - 636.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Marian and G. Sacks
Micronutrients and Older Adults
Nutr Clin Pract,
April 1, 2009;
24(2):
179 - 195.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. McKay, M. L. McCullough, R. G. Ziegler, P. Kraft, B. S. Saltzman, E. Riboli, A. Barricarte, C. D. Berg, G. Bergland, S. Bingham, et al.
Vitamin D Receptor Polymorphisms and Breast Cancer Risk: Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium
Cancer Epidemiol. Biomarkers Prev.,
January 1, 2009;
18(1):
297 - 305.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. C. Freedman and P. J. Goodwin
The Role of Vitamin D in Breast Cancer Recurrence
ASCO Educational Book,
January 1, 2009;
2009(1):
79 - 83.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Heist, W. Zhou, Z. Wang, G. Liu, D. Neuberg, L. Su, K. Asomaning, B. W. Hollis, T. J. Lynch, J. C. Wain, et al.
Circulating 25-Hydroxyvitamin D, VDR Polymorphisms, and Survival in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
December 1, 2008;
26(34):
5596 - 5602.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Hansdottir, M. M. Monick, S. L. Hinde, N. Lovan, D. C. Look, and G. W. Hunninghake
Respiratory Epithelial Cells Convert Inactive Vitamin D to Its Active Form: Potential Effects on Host Defense
J. Immunol.,
November 15, 2008;
181(10):
7090 - 7099.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L Neuhouser, B. Sorensen, B. W Hollis, A. Ambs, C. M Ulrich, A. McTiernan, L. Bernstein, S. Wayne, F. Gilliland, K. Baumgartner, et al.
Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors
Am. J. Clinical Nutrition,
July 1, 2008;
88(1):
133 - 139.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ng, J. A. Meyerhardt, K. Wu, D. Feskanich, B. W. Hollis, E. L. Giovannucci, and C. S. Fuchs
Circulating 25-Hydroxyvitamin D Levels and Survival in Patients With Colorectal Cancer
J. Clin. Oncol.,
June 20, 2008;
26(18):
2984 - 2991.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Cantor
Shedding Light on Vitamin D and Integrative Oncology
Integr Cancer Ther,
June 1, 2008;
7(2):
81 - 89.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Pilz, H. Dobnig, B. Winklhofer-Roob, G. Riedmuller, J. E. Fischer, U. Seelhorst, B. Wellnitz, B. O. Boehm, and W. Marz
Low Serum Levels of 25-Hydroxyvitamin D Predict Fatal Cancer in Patients Referred to Coronary Angiography
Cancer Epidemiol. Biomarkers Prev.,
May 1, 2008;
17(5):
1228 - 1233.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Van Renterghem
Lung Cancer Survival: Vitamin D Could Be Just a Marker of Physical Fitness
J. Clin. Oncol.,
December 1, 2007;
25(34):
5537 - 5538.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. D. Davis and J. T. Dwyer
The "Sunshine Vitamin": Benefits Beyond Bone?
J Natl Cancer Inst,
November 7, 2007;
99(21):
1563 - 1565.
[Full Text]
[PDF]
|
 |
|
|